Pre-procedural levels of erythrocyte sedimentation rate (ESR) and risk of clinical restenosis in patients with percutaneous coronary intervention and coronary stent placement [5]

Thrombosis and Haemostasis

Volumn 94, Issue 4, 2005, Pages 892-894

  Rana, Jamal S ^a,b   Monraats, Pascalle S ^a,c   Zwinderman, Aeilko H ^b   de Maat, Moniek P M ^d   Kastelein, John J P ^b   Agema, Willem R P ^a,c   Doevendans, Pieter A F ^e   de Winter, Robbert J ^b   Tio, René A ^f   Waltenberger, Johannes ^g   Frants, Rune R ^a   van der Laarse, Arnoud ^a   van der Wall, Ernst E ^a   Jukema, J Wouter ^a,c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEART DEATH; HEART MUSCLE ISCHEMIA; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; RESTENOSIS; REVASCULARIZATION; RISK ASSESSMENT; RISK FACTOR; SILENT MYOCARDIAL ISCHEMIA; STABLE ANGINA PECTORIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD SEDIMENTATION; CORONARY RESTENOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; STENTS;

EID: 27144486650     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (30)

1. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979; 301: 61-8.
2. Lowe HC, Oesterle SN, Khachigian LM. Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol 2002; 39: 183-93.
3. Buffon A, Liuzzo G, Biasucci LM et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999; 34: 1512-21.
4. Walter DH, Fichtlscherer S, Sellwig M et al.. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001; 37: 839-46.
5. Dibra A, Mehilli J, Braun S et al. Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. Am J Med 2003; 114: 715-22.
6. de Winter RJ, Koch KT, van Straalen JP et al. C-reactive protein and coronary events following percutaneous coronary angioplasty. Am J Med 2003; 115: 85-90.
7. Gomma AH, Hirschfield GM, Gallimore JR Jr et al. Preprocedural inflammatory markers do not predict restenosis after successful coronary stenting. Am Heart J 2004; 147: 1071-7.
8. Saadeh C. The erythrocyte sedimentation rate: old and new clinical applications. South Med J 1998; 3: 220-5.
9. Brigden M. The erythrocyte sedimentation rate: still a helpful test when used judiciously. Postgrad Med 1998; 103: 257-74.
10. Sox HC Jr, Liang MH. The erythrocyte sedimentation rate: guidelines for rational use. Ann Intern Med 1986; 104: 515-23.
11. Stuart J, Whicher JT. Tests for detecting and monitoring the acute phase response. Arch Dis Child 1988; 63: 115-7.
12. Katz PR, Karuza J, Gutman SI et al. A comparison between erythrocyte sedimentation rate (ESR) and selected acute-phase proteins in the elderly. Am J Clin Pathol 1990; 94: 637-40.
13. Andresdottir MB, Sigfusson N, Sigvaldason H et al. Erythrocyte sedimentation rate, an independent predictor of coronary heart disease in men and women: The Reykjavik Study. Am J Epidemiol 2003; 158: 844-51.
14. Carlson LA, Bottiger LE, Ahfeldt PE. Risk factors for myocardial infarction in the Stockholm prospective study. A 14-year follow-up focussing on the role of plasma triglycerides and cholesterol. Acta Med Scand 1979; 206: 351-60.
15. Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.
16. Gillum RF, Mussolino ME, Makuc DM. Erythrocyte sedimentation rate and coronary heart disease: the NHANES I Epidemiologic Follow-up Study. J Clin Epidemiol 1995; 48: 353-61.
17. Erikssen G, Liestol K, Bjornholt JV et al. Erythrocyte sedimentation rate: a possible marker of atherosclerosis and a strong predictor of coronary heart disease mortality. Eur Heart J 2000; 21: 1614-20.
18. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957; 17: 237-46.
19. Rafnsson V, Bengtsson C. Erythrocyte sedimentation rate and cardiovascular disease. Results from a population study of women in Goteborg, Sweden. Atherosclerosis 1982; 42: 97-107.
20. Tibblin G, Wilhelmsen L, Werko L. Risk factors for myocardial infarction and death due to ischemic heart disease and other causes. Am J Cardiol 1975; 35: 514-22.
21. Danesh J, Collins R, Peto R et al. Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J 2000; 21: 515-20.
22. Toutouzas K, Colombo A, Stefanadis C. Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J 2004;25: 1679-87.
23. Monraats PS, Rana JS, Zwinderman AH et al. -455 G/A polymorphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placement. Thromb Haemost 2005; 93: 564-9
24. Bhatt DL. Inflammation and restenosis: is there a link? Am Heart J 2004; 147: 945-7.
25. Gottsauner-Wolf M, Zasmeta G, Hornykewycz S et al. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J 2000; 21: 1152-8.
26. Fukuda D, Shimada K, Tanaka A et al. Circulating monocytes and instent neointima after coronary stent implantation. J Am Coll Cardiol 2004; 43: 18-23.
27. Hokimoto S, Ogawa H, Saito T et al. Increased plasma antigen levels of monocyte chemoattractant protein-1 in patients with restenosis after percutaneous transluminal coronary angioplasty. Jpn Circ J 2000; 64: 831-4.
28. Schillinger M, Exner M, Mlekusch W et al. Acute-phase response after stent implantation in the carotid artery: association with 6-month instent restenosis. Radiology 2003; 227: 516-21.
29. Agema WRP, Monraats PS, Zwinderman AH et al. Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era. Eur Heart J 2004; 25: 1163-70.
30. Garas SM, Huber P, Scott NA. Overview of therapies for prevention of restenosis after coronary interventions. Pharmacol Ther 2001; 92: 165-78.